External Validation of the 2019 Briganti Nomogram for the Identification of Prostate Cancer Patients Who Should Be Considered for an Extended Pelvic Lymph Node Dissection
Giorgio Gandaglia(Vita-Salute San Raffaele University), Alberto Briganti(Vita-Salute San Raffaele University), Roderick van den Bergh(European Association of Urology), Giancarlo Marra(Royal Free London NHS Foundation Trust), Paolo Gontero(Fondazione Ricerca Molinette), Derya Tilki(Koç University), Hendrik Borgmann(Goethe University Frankfurt), Alberto Martini(The University of Texas MD Anderson Cancer Center), C. Surcel(Institutul Clinic Fundeni), Igor Tsaur(Johannes Gutenberg University Mainz), Pieter De Visschere(Ghent University Hospital), Alexander Kretschmer(Ludwig-Maximilians-Universität München), Francesco Montorsi(Vita-Salute San Raffaele University), Armando Stabile(Royal Free London NHS Foundation Trust), Isabel Heidegger(Innsbruck Medical University), Nicola Fossati(Ospedale regionale di Lugano), Romain Mathiéu(Centre Hospitalier Universitaire de Rennes), Piet Ost(Ghent University Hospital), Guillaume Ploussard(Clinique Saint Jean Languedoc), Massimo Valério(University Hospital of Geneva), Fabian Steinkohl(Innsbruck Medical University)
Cited by 92
Related Papers
Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation
|The Lancet Oncology|2020|1.1k
The Lancet Commission on prostate cancer: planning for the surge in cases
|The Lancet|2024|694
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines
|European Urology|2023|656